Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine

202510 citationsJournal Article

Authors

David Fitzpatrick · East–West Center

Donald S McVinnie · Pfizer (United Kingdom)

Lisa A. Jackson · Kaiser Permanente Washington Health Research Institute

Graham Crowther · Pfizer (United Kingdom)

Anita Geevarughese · Pfizer (United States)

Kevin Cannon · PMG Research

Lucila García

Abstract

The modRNA vaccine had statistically superior efficacy over the control vaccine, with greater immune responses to A/H3N2 and A/H1N1 strains, but was associated with more reactogenicity events. (Funded by Pfizer; C4781004 ClinicalTrials.gov number, NCT05540522.)See also in <i>NEJM Evidence</i>: Human clinical trial of a nucleoside-modified mRNA influenza vaccine.

Topics & Keywords

Influenza Virus Research Studies RNA Interference and Gene Delivery Immune Response and Inflammation

Publication Details

Published in: New England Journal of Medicine

Volume 393, Issue 20, pp. 2001-2011

DOI: 10.1056/nejmoa2416779

Field-Weighted Citation Impact: 13.88

Command Palette

Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine

Authors

Abstract

Topics & Keywords

Publication Details